Searched for
OZEMPIC SALES
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
- India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...
- Why are Indians suddenly buying more vitamins after starting Ozempic-like weight loss drugs?Demand for vitamin and nutritional supplements is surging in India. This trend follows the increased availability of semaglutide-based weig...
- CEOs are getting ruthless about worker performanceCorporate leaders are increasingly prioritizing results over employee comfort, with CEOs like Unilever's Fernando Fernandez demanding "volu...
- Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh inDr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared w...
- Counterfeit Mounjaro case: Eli Lilly issues statement after Gurugram drug racket exposedGurugram's law enforcement has taken a bold step by breaking up a ring creating counterfeit Mounjaro injections, with two individuals now i...
- Weight-loss drug craze for Ozempic, Mounjaro surges in India amid safety concernsIn India, appetite for weight-loss drugs is on the rise, with consumers increasingly turning to injectables such as Mounjaro and Ozempic fo...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Novo Nordisk's 'Semaglutide' gains weight against Eli Lilly in battle for market shareNovo Nordisk's diabetes and weight-loss drug semaglutide is rapidly gaining ground in India. It is now challenging Eli Lilly's tirzepatide ...
- Eli Lilly's Mounjaro added to China's state insurance list for diabetes treatmentEli Lilly's diabetes drug Mounjaro will be added to China's state health insurance from January 1, making it more accessible to the country...
- Weight-loss drug Ozempic to debut in India soonNovo Nordisk will launch Ozempic in India. This injectable drug manages type 2 diabetes and aids weight loss. It enters a competitive marke...
- Novo Nordisk's stock rises as Ozempic beat analysts' expectations in salesIn its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage notifications'.
- Novo Nordisk not yet ready to bring in popular obesity, diabetes injectablesNovo Nordisk's launch of weight-loss and diabetes drugs Wegovy and Ozempic in India hinges on resolving supply issues. The company is scali...
- Biocon seeks partner to test generic Wegovy, Ozempic in ChinaIndia's Biocon is seeking a Chinese partner to conduct clinical trials on generic versions of Novo Nordisk's popular diabetes drug Ozempic ...
- Ozempic: Bengaluru is the secret ingredient behind the wonder weight loss drugs' successNovo Nordisk's India team played a pivotal role in the success of Ozempic, a semaglutide-based drug for diabetes and weight management. The...
- Indiamart working with Novo Nordisk to halt illegal Wegovy salesThe drugmaker's India legal team held discussions with Indiamart's top executives to develop a "framework" for regularly alerting the onlin...
- Fake weight loss injections leave people in comas, urgent safety alert issuedFake weight loss injections, falsely marketed as Ozempic or Saxenda, have triggered significant safety alarms in the United Kingdom. Author...
- Corporate America weighs risks of the Ozempic effectU.S. companies in various sectors, including food and beverage, medical devices, and dialysis services, are facing questions from investors...
- Nestlé responds to weight-loss drug surge: Developing health aids for Ozempic, Wegovy usersNestlé, the global food leader, is responding to the growing trend of appetite-suppressing weight-loss medications like Ozempic, Wegovy, an...
Load More
